Gene Therapy: Four-Month Lag In Commercial Access Protects EMBARK Study, Sarepta Says

 
• By Sue Sutter

Company’s prediction that Duchenne muscular dystrophy patients likely would not be able to access SRP-9001 until four months after accelerated approval eased some US FDA panelists’ concerns about interference with the ongoing confirmatory trial.

Mind the gap
The gap between accelerated approval of SRP-9001 and commercial access will be at least 8 weeks and more likely about 4 months, Sarepta says. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers